Treatments for mitochondrial dysfunction associated with autism spectrum disorders

Journal of Pediatric Biochemistry

Volumn 2, Issue 4, 2012, Pages 241-249

  Frye, Richard E ^a   Rossignol, Daniel A ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Rossignol Medical Center   (United States)

Author keywords

Autism spectrum disorder; mitochondrial disease; oxidative stress; treatment

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ASCORBIC ACID; BIOTIN; CARNITINE; CREATINE; FOLINIC ACID; LEVACECARNINE; MECOBALAMIN; NICOTINIC ACID; PLACEBO; PYRIDOXINE; RIBOFLAVIN; THIAMINE; THIOCTIC ACID; UBIDECARENONE;

AUTISM; CEREBROVASCULAR ACCIDENT; CHILD; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; DEHYDRATION; DIABETES MELLITUS; DIET RESTRICTION; DIET THERAPY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG USE; DUCHENNE MUSCULAR DYSTROPHY; ENERGY TRANSFER; FATTY ACID OXIDATION; FEVER; FOOD ALLERGY; FRIEDREICH ATAXIA; HEALTH CARE QUALITY; HUMAN; HUNTINGTON CHOREA; INFECTION; KEARNS SAYRE SYNDROME; LACTIC ACIDOSIS; METABOLIC DECOMPENSATION; METABOLIC DISORDER; MITOCHONDRIAL ENCEPHALOPATHY; MUSCULAR DYSTROPHY; NONHUMAN; NUTRITIONAL INTOLERANCE; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RESPIRATORY CHAIN; REVIEW; VACCINATION; VITAMIN SUPPLEMENTATION;

EID: 84877868916     PISSN: 18795390     EISSN: 18795404     Source Type: Journal    
DOI: 10.3233/JPB-120065     Document Type: Review

References (79)

1. Rossignol DA, Frye RE. Mitochondrial dysfunction in autism spectrum disorders: A systematic review and meta-analysis. Mol Psychiatry 2012; 17: 290-314.
2. Frye RE. Biomarker of abnormal energy metabolism in children with autism spectrum disorder. N A J Med Sci 2012; 5: 141-147.
3. Giulivi C, Zhang YF, Omanska-Klusek A, et al.Mitochondrial dysfunction in autism. JAMA 2010; 304: 2389-2396.
4. Chinnery PF, Turnbull DM. Epidemiology and treatment of mitochondrial disorders. Am J Med Genet 2001; 106: 94-101.
5. Pfeffer G, Majamaa K, Turnbull DM, Thorburn D, Chinnery PF. Treatment formitochondrial disorders. CochraneDatabase Syst Rev 2012; 4: CD004426.
6. Barshop B, Summar M. Attitudes regarding vaccination among practitioners of clinical biochemical genetics. Mol Genet Metab 2008; 95: 1-2.
7. Edmonds JL, Kirse DJ, Kearns D, Deutsch R, Spruijt L, Naviaux RK. The otolaryngological manifestations of mitochondrial disease and the risk of neurodegeneration with infection. Arch Otolaryngol Head Neck Surg 2002; 128: 355-362.
8. Shoffner J, Hyams L, Langley GN, et al. Fever plus mitochondrial disease could be risk factors for autistic regression. J Child Neurol 2010; 25: 429-434.
9. Poling JS, Frye RE, Shoffner J, Zimmerman AW. Developmental regression and mitochondrial dysfunction in a child with autism. J Child Neurol 2006; 21: 170-172.
10. Parikh S, Saneto R, Falk MJ, et al. A modern approach to the treatment of mitochondrial disease. Curr Treat Options Neurol 2009; 11: 414-430.
11. Schultz ST, Klonoff-Cohen HS, Wingard DL, Akshoomoff NA, Macera CA, Ji M. Acetaminophen (paracetamol) use, measles-mumps-rubella vaccination, and autistic disorder: the results of a parent survey. Autism 2008; 12: 293-307.
12. Good P. Did acetaminophen provoke the autism epidemic? Altern Med Rev 2009; 14: 364-372.
13. Hinson JA, Reid AB, McCullough SS, James LP. Acetaminophen-induced hepatotoxicity: role of metabolic activation, reactive oxygen/nitrogen species, and mitochondrial permeability transition. Drug Metab Rev 2004; 36: 805-822.
14. Jaeschke H, McGill MR, Ramachandran A. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. Drug Metab Rev 2012; 44: 88-106.
15. Zelnik N, Axelrod FB, Leshinsky E,GriebelML,Kolodny EH. Mitochondrial encephalomyopathies presenting with features of autonomic and visceral dysfunction. Pediatr Neurol 1996; 14: 251-254.
16. Neustadt J, Pieczenik SR. Medication-induced mitochondrial damage and disease. Mol Nutr Food Res 2008; 52: 780-788.
17. Finsterer J, Zarrouk Mahjoub S. Mitochondrial toxicity of antiepileptic drugs and their tolerability in mitochondrial disorders. Expert Opin Drug Metab Toxicol 2012; 8: 71-79.
18. Berger I, Segal I, Shmueli D, Saada A. The effect of antiepileptic drugs on mitochondrial activity: A pilot study. J Child Neurol 2010; 25: 541-545.
19. Edmonds JL, Jr. Surgical and anesthetic management of patients with mitochondrial dysfunction. Mitochondrion 2004; 4: 543-548.
20. Lim S, Cho YM, Park KS, Lee HK. Persistent organic pollutants, mitochondrial dysfunction, and metabolic syndrome. Ann N Y Acad Sci 2010; 1201: 166-176.
21. Crinnion WJ. Environmental medicine, part three: long-term effects of chronic low-dose mercury exposure. Altern Med Rev 2000; 5: 209-223.
22. Armani C, Landini L, Jr., Leone A. Molecular and biochemical changes of the cardiovascular system due to smoking exposure. Curr Pharm Des 2009; 15: 1038-1053.
23. Houston MC. The role of mercury and cadmium heavy metals in vascular disease, hypertension, coronary heart disease, and myocardial infarction. Altern Ther Health Med 2007; 13: S128-133.
24. Hatakeyama S, Kawase S, Yoshimura I. Comparative oral toxicity of coenzyme Q10 and its (2Z)-isomer in rats: single and four-week repeated dose toxicity studies. J Nutr Sci Vitaminol 2006; 52: 9-20.
25. Abdin AA, Hamouda HE. Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenoneinduced parkinsonism. Neuropharmacology 2008; 55: 1340- 1346.
26. Sourris KC, Harcourt BE, Tang PH, et al. Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes. Free Radic Biol Med 2012; 52: 716-723.
27. Lopez LC, Schuelke M, Quinzii CM, et al. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2)mutations. AmJ Med Genet 2006; 79: 1125-1129.
28. Horvath R, Schneiderat P, Schoser BG, et al. Coenzyme Q10 deficiency and isolated myopathy. Neurology 2006; 66: 253- 255.
29. Le Ber I, Dubourg O, Benoist JF, et al. Muscle coenzyme Q10 deficiencies in ataxia with oculomotor apraxia 1. Neurology 2007; 68: 295-297.
30. Lamperti C, Naini A, Hirano M, et al. Cerebellar ataxia and coenzyme Q10 deficiency. Neurology 2003; 60: 1206-1208.
31. Cooper JM, Korlipara LV, Hart PE, Bradley JL, Schapira AH. Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur J Neurol 2008; 15: 1371-1379.
32. Miles MV, Putnam PE, Miles L, et al. Acquired coenzyme Q10 deficiency in children with recurrent food intolerance and allergies. Mitochondrion 2011; 11: 127-135.
33. KurupRK,Kurup PA.Ahypothalamic digoxin-mediatedmodel for autism. Int J Neurosci 2003; 113: 1537-1559.
34. Ogasahara S, Nishikawa Y, Yorifuji S, et al. Treatment of Kearns-Sayre syndrome with coenzyme Q10. Neurology 1986; 36: 45-53.
35. Rodriguez MC, MacDonald JR, Mahoney DJ, Parise G, Beal MF, Tarnopolsky MA. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 2007; 35: 235-242.
36. Glover EI, Martin J, Maher A, Thornhill RE, Moran GR, Tarnopolsky MA. A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle Nerve 2010; 42: 739-748.
37. Arrigoni-Martelli E, Caso V. Carnitine protects mitochondria and removes toxic acyls from xenobiotics. Drugs Exp Clin Res 2001; 27: 27-49.
38. Ringseis R,Keller J, Eder K. Role of carnitine in the regulation of glucose homeostasis and insulin sensitivity: evidence from in vivo and in vitro studies with carnitine supplementation and carnitine deficiency. Eur J Nutr 2012; 51: 1-18.
39. Jun DW, Cho WK, Jun JH, et al. Prevention of free fatty acid-induced hepatic lipotoxicity by carnitine via reversal of mitochondrial dysfunction. Liver Int 2011; 31: 1315-1324.
40. Scafidi S, Racz J, Hazelton J, McKenna MC, Fiskum G. Neuroprotection by acetyl-L-carnitine after traumatic injury to the immature rat brain. Dev Neurosci 2010; 32: 480-487.
41. Patel SP, Sullivan PG, Lyttle TS, Rabchevsky AG. Acetyl- L-carnitine ameliorates mitochondrial dysfunction following contusion spinal cord injury. J Neurochem 2010; 114: 291- 301.
42. Bender A, Auer DP, Merl T, et al. Creatine supplementation lowers brain glutamate levels inHuntington's disease. JNeurol 2005; 252: 36-41.
43. Tarnopolsky MA. Clinical use of creatine in neuromuscular and neurometabolic disorders. Subcell Biochem 2007; 46: 183-204.
44. Pan JW, Takahashi K. Cerebral energetic effects of creatine supplementation in humans. Am J Physiol Regul Integr Comp Physiol 2007; 292: R1745-1750.
45. Guidi C, Potenza L, Sestili P, et al. Differential effect of creatine on oxidatively-injured mitochondrial and nuclear DNA. Biochim Biophys Acta 2008; 1780: 16-26.
46. Berneburg M, Gremmel T, Kurten V, et al. Creatine supplementation normalizes mutagenesis of mitochondrial DNA as well as functional consequences. J Invest Dermatol 2005; 125: 213-220.
47. Rae C, Digney AL, McEwan SR, Bates TC. Oral creatine monohydrate supplementation improves brain performance: A double-blind, placebo-controlled, cross-over trial. Proc Biol Sci 2003; 270: 2147-2150.
48. Banerjee B, Sharma U, Balasubramanian K, Kalaivani M, Kalra V, Jagannathan NR. Effect of creatine monohydrate in improving cellular energetics and muscle strength in ambulatory Duchenne muscular dystrophy patients: a randomized, placebo-controlled 31P MRS study. Magn Reson Imaging 2010; 28: 698-707.
49. TarnopolskyMA, Mahoney DJ, Vajsar J, et al. Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology 2004; 62: 1771-1777.
50. Walter MC, Lochmuller H, Reilich P, et al. Creatine monohydrate in muscular dystrophies: A double-blind, placebocontrolled clinical study. Neurology 2000; 54: 1848-1850.
51. Escolar DM, Buyse G, Henricson E, et al. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Ann Neurol 2005; 58: 151-155.
52. Shefner JM, Cudkowicz ME, Schoenfeld D, et al. A clinical trial of creatine in ALS. Neurology 2004; 63: 1656-1661.
53. Komura K, Hobbiebrunken E,Wilichowski EK, Hanefeld FA. Effectiveness of creatine monohydrate in mitochondrial encephalomyopathies. Pediatr Neurol 2003; 28: 53-58.
54. Tarnopolsky MA, Roy BD, MacDonald JR, Arandomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies, Muscle Nerve 1997; 20: 1502-1509.
55. Kornblum C, Schroder R, Muller K, et al. Creatine has no beneficial effect on skeletal muscle energy metabolism in patients with single mitochondrial DNA deletions: A placebocontrolled, double-blind 31P-MRS crossover study. Eur JNeurol 2005; 12: 300-309.
56. Atkuri KR, Cowan TM, Kwan T, et al. Inherited disorders affecting mitochondrial function are associated with glutathione deficiency and hypocitrullinemia. Proc Natl Acad Sci USA 2009; 106: 3941-3945.
57. Horvath R, Gorman G, Chinnery PF. How can we treat mitochondrial encephalomyopathies? Approaches to therapy. Neurotherapeutics 2008; 5: 558-568.
58. Finsterer J. Treatment of mitochondrial disorders. Eur J Paediatr Neurol 2010; 14: 29-44.
59. Lee SK, Kim J, Kim HD, Lee JS, Lee YM. Initial experiences with proton MR spectroscopy in treatment monitoring of mitochondrial encephalopathy. Yonsei Med J 2010; 51: 672-675.
60. Garcia-Cazorla A, Quadros EV, Nascimento A, et al. Mitochondrial diseases associated with cerebral folate deficiency. Neurology 2008; 70: 1360-1362.
61. Mostafa GA, El-Gamal HA, El-Wakkad ASE, El-Shorbagy OE, Hamza MM. Polyunsaturated fatty acids, carnitine and lactate as biological markers of brain energy in autistic children. Int J Child Neuropsychiatry 2005; 2: 179-188.
62. Filipek PA, Juranek J, Nguyen MT, Cummings C, Gargus JJ. Relative carnitine deficiency in autism. J Autism Dev Disord 2004; 34: 615-623.
63. Pastural E, Ritchie S, Lu Y, et al. Novel plasma phospholipid biomarkers of autism: mitochondrial dysfunction as a putative causative mechanism. Prostaglandins Leukot Essent Fatty Acids 2009; 81: 253-264.
64. Filipek PA, Juranek J, Smith M, et al. Mitochondrial dysfunction in autistic patients with 15q inverted duplication. Ann Neurol 2003; 53: 801-804.
65. Gargus JJ, Lerner MA. Familial autism with primary carnitine deficiency, sudden death, hypotonia and hypochromic anemia. Am J Human Gen 1997; 61: A98.
66. Gargus JJ, Imtiaz F. Mitochondrial energy-deficient endophenotype in autism. Am J Biochem Biotech 2008; 4: 198-207.
67. Ezugha H, Goldenthal M, Valencia I, Anderson CE, Legido A, Marks H. 5q14.3 Deletion Manifesting as Mitochondrial Disease and Autism: Case Report. J Child Neurol 2010; 25: 1232-1235.
68. Geier DA, Kern JK, Davis G, et al. A prospective doubleblind, randomized clinical trial of levocarnitine to treat autism spectrum disorders. Med Sci Monit 2011; 17: PI15-23.
69. Fahmy SF, El-hamamsy MH, Zaki OK, Badary OA. l- Carnitine supplementation improves the behavioral symptoms in autistic children. Res Aut Spect Dis 2013; 7: 159-66.
70. Adams JB, Holloway C. Pilot study of a moderate dose multivitamin/ mineral supplement for children with autistic spectrum disorder. J Altern Complement Med 2004; 10: 1033- 1039.
71. Adams JB, Audhya T, McDonough-Means S, et al. Effect of a vitamin/mineral supplement on children and adults with autism. BMC Pediatr 2011; 11: 111.
72. James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 2004; 80: 1611-1617.
73. James SJ, Melnyk S, Fuchs G, et al. Efficacy of methylcobalamin and folinic acid treatment on glutathione redox status in children with autism. Am J Clin Nutr 2009; 89: 425-430.
74. Hardan AY, Fung LK, Libove RA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry 2012; 71: 956-961.
75. Rossignol DA. Novel and emerging treatments for autism spectrum disorders: a systematic review. Ann Clin Psychiatry 2009; 21: 213-236.
76. Dolske MC, Spollen J, McKay S, Lancashire E, Tolbert L. A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17: 765-74.
77. Chez MG, Buchanan CP, Aimonovitch MC, Becker M, Schaefer K, Black C, et al. Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. J Child Neurol 2002; 17: 833-837.
78. Freedenfeld SH, Hamada K, Audhya T, Adams JB. Biochemical effects of ribose and NADH therapy in children with autism. Autism Insights 2011; 3: 3-13.
79. Evangeliou A, Vlachonikolis I, Mihailidou H, et al. Application of a ketogenic diet in children with autistic behavior: pilot study. J Child Neurol 2003; 18: 113-118.